Диссертация (1154752), страница 24
Текст из файла (страница 24)
567–573126.Incidence of adverse drug reactions in paediatric in/out-patients: asystematic review and meta-analysis of prospective studies [Text] / P.Impicciatore, I. Choonara, A. Clarkson, D. Provasi, C. Pandolfini, M. Bonati //Br J Clin Pharmacol. – 2001. – Vol.
52, № 1. – P. 77–83.127.Incidence of serious adverse drug reactions in general practice: aprospective study [Text] / C. Lacoste-Roussillon, P. Pouyanne, F. Haramburu [etal.] // Clin Pharmacol Ther. – 2001. – Vol. 69, № 6. – P. 458–462128.Incidence, characteristics and risk factors of adverse drug reactions inhospitalized children - a prospective observational cohort study of 6,601admissions [Electronic resource] / S. Thiesen, E.J.
Conroy, J.R. Bellis [et al.] //BMCMed.–2013.–Vol.11.–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225679/pdf/1741-7015-11237.pdf. – (accessed: 04.01.2017)129.Jobanputra, N. Off-label and unlicensed drug use in children admitted toPediatric Intensive Care Units (PICU) [Text] / N. Jobanputra, S.U. Save, S.B.Bavdekar // Int J Risk Saf Med. – 2015. – Vol.
27, № 3. – P. 113–121130.Keller-Stanislawski, B. Adverse events following immunisation inGermany from 1.1.2001 to 31.12.2003 [Text] / B. Keller-Stanislawski, N. Heuss,C. Meyer // Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.– 2004. – Vol. 47, № 12. – P. 1151–1164131.Khan, L.M.
Comparative epidemiology of hospital-acquired adverse drugreactions in adults and children and their impact on cost and hospital stay – asystematic review [Text] / L.M. Khan // Eur J Clin Pharmacol. – 2013. – Vol.69, № 12. – P. 1985–1996140132.Kutty, N. Treating children without antibiotics in primary healthcare.[Text] / N. Kutty // Oman Med J. – 2011. – Vol. 26, № 5.
– P. 303–305133.Lajoinie, A. Oral formulation of choice for children [Text] / A. Lajoinie, E.Henin, B. Kassai // Arch Pediatr. – 2015. – Vol. 22, № 8. – P. 877–885134.Langerová, P. Adverse drug reactions causing hospital admissions inchildhood: a prospective, observational, single-centre study [Text] / P.Langerová, J. Vrtal, K.
Urbánek // Basic Clin Pharmacol Toxicol. – 2014. – Vol.115, № 6. – P. 560–564135.Langerová, P. Incidence of unlicensed and off-label prescription in children[Electronic resource] / P. Langerová, J. Vrtal, K. Urbánek // Ital J Pediatr. –2014.–Vol.40.–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915231/pdf/1824-7288-4012.pdf. – (accessed: 17.01.2017)136.Lee, J.L. Unlicensed and off-label use of medicines in children admitted tothe intensive care units of a hospital in Malaysia [Text] / J.L. Lee, A.M.Redzuan, N.M. Shah // Int J Clin Pharm. – 2013. – Vol.
35, № 6. – P. 1025–1029137.Leśniak, M. Life-threatening drug reactions in children [Text] / M.Leśniak, J. Woron, E. Czarnobilska // Przegl Lek. – 2013. – Vol. 70, № 12. –P. 1003–1007138.Nature, occurrence and consequences of medication-related adverse eventsduring hospitalization: a retrospective chart review in the Netherlands [Text] /L.H. Hoonhout, M.C. de Bruijne, C. Wagner, H. Asscheman [et al.] // Drug Saf.– 2010. – Vol. 33, № 10. – P.
853–864139.Nifedipine versus fenoterol in the management of preterm labor: arandomized, multicenter clinical study [Text] / E. Valdés, H. Salinas, V. Toledo[et al.] // Gynecol Obstet Invest. – 2012. – Vol. 74, № 2. – P. 109–115140.Nikbakht, R. Nifedipine compared to magnesium sulfate for treatingpreterm labor: A randomized clinical trial [Text] / R. Nikbakht, M. TaheriMoghadam, H. Ghane'ee // Iran J Reprod Med. – 2014. – Vol. 12, № 2. – P.145–150141141.Off-label and unlicensed drug use: Results from a pilot study in a pediatricintensive care unit [Text] / I. García-López, J.E. Fuentes-Ríos, S. ManriqueRodríguez, M.
C. Fernández-Llamazares // An Pediatr (Barc). – 2017. – Vol. 86,№ 1. – P. 28–36142.Off-label and unlicensed medicines to hospitalised children in Norway[Electronic resource] // A. Teigen, S. Wang, B.T. Truong, K. Bjerknes J //Pharm Pharmacol. – 2016. – URL: doi: 10.1111/jphp.12581. – (accessed:23.05.2017)143.Off-label and unlicensed use of medicinal products in the neonatal settingin the Slovak Republic [Text] / J. Schweigertova, A. Durisova, D. Dolnikova [etal.] // Pediatr Int. – 2016.
– Vol. 58, № 2. – P. 126–131144.Off-label and unlicensed utilisation of medicines in a French paediatrichospital [Text] / P. Joret-Descout, S. Prot-Labarthe, F. Brion [et al.] // Int J ClinPharm. – 2015. – Vol. 37, № 6. – P. 1222–1227145.Off-label drug prescriptions among outpatient children and adolescents inGermany--a database analysis [Text] / D.
Sonntag, D. Trebst, W. Kiess [et al.] //Dtsch Med Wochenschr. – 2013. – Vol. 138, № 44. – P. 2239–2245146.Off-label drug use in a single-center pediatric cardiac intensive care unit[Text] / L.A. Maltz, D. Klugman, M.C. Spaeder, D.L.Wessel // World J PediatrCongenit Heart Surg. – 2013. – Vol. 4, № 3. – P. 262–266147.Off-label drug use in hospitalized children [Text] / S.S. Shah, M. Hall,D.M. Goodman [et al.] // Arch Pediatr Adolesc Med. – 2007. – Vol. 161, № 3. –P. 282–290148.Off-label medicine use in children and adolescents: results of a population-based study in Germany [Electronic resource] / H. Knopf, I.K. Wolf, G. Sarganas[et al.] // BMC Public Health. – 2013. – Vol.13.
–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706213/pdf/1471-2458-13631.pdf. – (accessed: 28.12.2016)149.Off-label prescribing in pediatric outpatients [Text] / A. Palmaro, R.Bissuel, N. Renaud [et al.] // Pediatrics. – 2015. – Vol. 135, №1. – P. 49–58142150.Off-labelprescribingtochildreninprimary care:retrospectiveobservational study [Text] / S. Ekins-Daukes, P.J. Helms, C.R. Simpson [et al.] //Eur J Clin Pharmacol. – 2004.
– Vol. 60, № 5. – P. 349–353151.Off-label use and harmful potential of drugs in a NICU in Brazil: Adescriptive study [Electronic resource] / A.S. de Souza, D.B. Dos Santos, L.C.Rey[etal.]//BMCPediatr.–2016.–Vol.–16.URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722776/pdf/12887_2016_Article_551.pdf. – (accessed: 20.12.2016)152.PaediatricadversedrugreactionsreportedtotheSpanishPharmacovigilance System from 2004 to 2009 [Text] / A.
Aldea, M. GarcíaSánchez-Colomer, E. Fernández Quintana, M. García Sáiz // Eur J ClinPharmacol. – 2012. – Vol. 68, № 9. – P. 1329–1338153.Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit andPrioritizing Future Research [Text] / A.S. Czaja, P.D.Reiter, M.L. Schultz, R.J.Valuck // J Pediatr Pharmacol Ther. – 2015. – Vol. 20, № 3. – P. 186–196154.Pediatric drug safety surveillance in Italian pharmacovigilance network: anoverview of adverse drug reactions in the years 2001 – 2012 [Electronicresource] / C.
Ferrajolo, A. Capuano, G. Trifirò [et al.] // Expert Opin Drug Saf.– 2014. – Suppl 1. – URL: doi: 10.1002/jcph.75. – (accessed: 17.04.2016)155.Pediatric hospital admission due to adverse drug reactions: Report from atertiary center [Text] / K. Gholami, F. Babaie, G.
Shalviri, M.R. Javadi, T.Faghihi // J Res Pharm Pract. – 2015. – Vol. 4, № 4. – P. 212–215156.Pharmacovigilance Risk Assessment Committee (PRAC) [Electronicresource]//EuropeanMedicinesAgency.–URL:http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp. – (accessed: 22.02.2017)157.Pirmohamed M. Adverse drug reactions and off-label and unlicensedmedicines in children: a nested case-control study of inpatients in a pediatrichospital [Electronic resource] / J.R. Bellis, J.J. Kirkham, S. Thiesen [et al.] //BMCMed.–2013.–Vol.11.–143https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231613/pdf/1741-7015-11238.pdf.
– (accessed: 16.03.2017)158.Prescribers' indications for drugs in childhood: a survey of five Europeancountries (Spain, France, Bulgaria, Slovakia and Russia) [Text] / E.J. Sanz, M.A.Hernández, S. Ratchina [et al.] // Acta Paediatr. – 2005. – Vol. 94, № 12.
– P.1784–1790159.Prescribing for off-label use and unauthorized medicines in three paediatricwards in Finland, the status before and after the European Union PaediatricRegulation [Text] / L. Lindell-Osuagwu, M. Hakkarainen, K. Sepponen,K.Vainio [et al.] // J Clin Pharm Ther. – 2014. – Vol. 39, № 2.
– P. 144–153160.Prescription drug dispensing profiles for one million children: a population-based analysis [Text] / T. Zhang, M.A. Smith, P.G. Camp [et al.] // Eur J ClinPharmacol. – 2013. – Vol. 69, № 3. – P. 581–588161.Pugeat, M. Insulin resistance, polycystic ovary syndrome and metformin[Text] / M.
Pugeat, P.H. Ducluzeau // Drugs. – 1999. – Vol. 58, Suppl. 1. – P.41–46162.Questions and Answers on FDA's Adverse Event Reporting System(FAERS)//FoodandDrugAdministration.–URL:https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/. – (accessed: 22.02.2017)163.Reported Adverse Drug Reactions in Infants: A Nationwide Analysis inMalaysia [Electronic resource] / R. Rosli, A.F. Dali, N.A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
